El interés en corto de Moderna da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Moderna. Los datos de interés en corto se actualizan cada dos semanas.

Moderna (NASDAQ:MRNA) Bolsa, Informe de interés en corto

MODERNA INC

Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Volatilidad

Markets

Media

GRAL

MRNA

Volatilidad y nerviosismo sacuden los mercados por las políticas comerciales impredecibles de Trump. ¿Qué podría pasar ahora?

Analistas advierten impacto financiero si Trump no redefine su estrategia comercial pronto

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

$BTC

DOMH

LCID

NVDA

TSLA

El mercado bursátil de Estados Unidos enfrentó una jornada complicada ayer, ya que el sentimiento de riesgo continuó bajo presión en Wall Street. El índice S&amp;P 500 vivió una sesión volátil, alcanzando su punto más bajo en más de seis meses antes de recuperar parte de sus pérdidas.

Nvidia, Moderna, Lucid, Dominari, Tesla: 5 acciones que están en el radar de los inversores

Large Cap

Health Care

General

CVAC

NVAX

Un trabajador lechero en Nevada da positivo en gripe aviar H5N1. CDC investiga mientras la cepa se propaga en aves y ganado.

Gripe aviar en EE.UU.: trabajador lechero en Nevada da positivo

Moderna Inc

Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">them for broader use</a>.
The decision reflects a growing pattern of vaccine restrictions under the leadership of the U.S. Health and Human Services Secretary Robert F. Kennedy Jr.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a>
However, citing federal documents released Wednesday, ABC News reported <a target="_blank" href="https://abcnews.go.com/Health/wireStory/fda-vaccine-official-restricted-covid-vaccine-approvals-advice-123431749" rel="noreferrer noopener">that</a> Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
In a five-page memo, Prasad wrote that &#8220;even rare vaccination-related harms, both known and unknown, now have a higher chance of outweighing potential benefits,&#8221; highlighting the need for more cautious vaccine policy.
The vaccines were eventually approved in May, but under the narrower eligibility <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45537919/fda-limits-annual-covid-19-boosters-to-high-risk-americans-demands-new-trials-for-healthy-adults-in-policy-shift-under-rfk-jr" rel="noreferrer noopener">criteria dictated by Prasad</a>.
Novavax&#8217;s shot, Nuvaxovid, is the only protein-based COVID vaccine available in the U.S., while Moderna&#8217;s mNexspike is a lower-dose, updated version of its <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">original mRNA-based vaccine</a>.
Prasad also cited the risk of myocarditis, a rare heart inflammation, especially in younger people, as a key reason for restricting Moderna&#8217;s shot.
He directed the company to conduct further studies as a condition for approval. The FDA also added updated warning labels for Moderna and Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) vaccines regarding myocarditis, though external researchers say such cases are typically mild and resolve quickly.
Top FDA leaders rarely intervene in the product review, making Prasad&#8217;s decision notable. He was appointed in May after Dr. Peter Marks resigned over policy disagreements with Kennedy.
In May, Kennedy, in a&nbsp;video&nbsp;posted to the social media platform X, announced that the COVID-19 vaccine will no longer be among the recommended vaccines for pregnant women and healthy children on the U.S. Centers for Disease Control and <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Prevention&#8217;s immunization schedule</a>.
Price Action: At the last check on Thursday, Moderna (MRNA) stock saw an increase of 1.34%, trading at $30.69, while Novavax (NVAX) stock rose by 0.67% to $6.81. Pfizer (PFE) stock was also up at the last check.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/contracts/25/07/46249640/astrazeneca-in-15b-talks-for-drug-that-could-upend-lung-cancer-treatment" target="_blank" rel="noreferrer noopener">AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment</a></li>
</ul>
Photo via Shutterstock

Biotech

Government

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval

<a href="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html" title="https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html">https://www.nytimes.com/2025/07/02/health/fda-covid-vaccines.html</a>

BNTX

'Top F.D.A. Official Overrode Scientists on Covid Shots; Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.' - NY Times

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$157.50</td>
<td>$94.8K</td>
<td>1.5K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$30.00</td>
<td>$25.7K</td>
<td>980</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$29.5K</td>
<td>10</td>
<td>899</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$307.50</td>
<td>$37.3K</td>
<td>1.1K</td>
<td>437</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$20.00</td>
<td>$37.7K</td>
<td>1.0K</td>
<td>431</td>
</tr>
<tr>
<td>PRME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$27.5K</td>
<td>24</td>
<td>100</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$60.00</td>
<td>$161.0K</td>
<td>827</td>
<td>100</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.00</td>
<td>$46.7K</td>
<td>14.6K</td>
<td>67</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$75.00</td>
<td>$26.5K</td>
<td>387</td>
<td>61</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$340.00</td>
<td>$90.7K</td>
<td>11</td>
<td>56</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on July 18, 2025. Parties traded 465 contract(s) at a $157.50 strike. The total cost received by the writing party (or parties) was $94.8K, with a price of $204.0 per contract. There were 1504 open contracts at this strike prior to today, and today 1579 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on July 11, 2025. This event was a transfer of 211 contract(s) at a $30.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $122.0 per contract. There were 980 open contracts at this strike prior to today, and today 1094 contract(s) were bought and sold. 
• Regarding CNC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), we observe a call option sweep with bullish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $35.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $590.0 per contract. There were 10 open contracts at this strike prior to today, and today 899 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on July 18, 2025. This event was a transfer of 65 contract(s) at a $307.50 strike. The total cost received by the writing party (or parties) was $37.3K, with a price of $575.0 per contract. There were 1172 open contracts at this strike prior to today, and today 437 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option trade that happens to be bearish, expiring in 142 day(s) on November 21, 2025. This event was a transfer of 65 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $37.7K, with a price of $580.0 per contract. There were 1022 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• For PRME (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on October 17, 2025. This event was a transfer of 100 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $275.0 per contract. There were 24 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option trade that happens to be bullish, expiring in 898 day(s) on December 17, 2027. This event was a transfer of 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $161.0K, with a price of $1610.0 per contract. There were 827 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $46.7K, with a price of $4673.0 per contract. There were 14663 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 142 day(s) on November 21, 2025. Parties traded 45 contract(s) at a $75.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $590.0 per contract. There were 387 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we observe a call option sweep with bearish sentiment. It expires in 79 day(s) on September 19, 2025. Parties traded 24 contract(s) at a $340.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $90.7K, with a price of $3768.0 per contract. There were 11 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

PRME

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

WIIM

Moderna shares are trading higher. The stock may be experiencing continued strength after the company, on Monday, reported results from its Phase 3 efficacy study evaluating its mRNA-1010 seasonal influenza vaccine in adults.

<a href="https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true</a>

'RFK Jr. Vows Overhaul of Lawsuit-Sparing Vaccine Injury Program'- Bloomberg

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) on Monday revealed results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the company&#8217;s seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">aged 50 years and older</a>.
mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%).
Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors, and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/ac46164898/moderna-announces-positive-phase-3-results-for-seasonal-influenza-vaccine" rel="noreferrer noopener">an rVE of 27.4%</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45887132/novavaxs-experimental-covid-19-influenza-combo-shot-shows-immune-response-among-older-adults-in-phase-3-trial" rel="noreferrer noopener">Novavax&#8217;s Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial</a>
In a previous Phase 3 study, mRNA-1010 had demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine.
According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season.
Over 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs and widespread disruption to daily life and work.
The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.
The safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. The majority of solicited adverse reactions (SARs) were mild.
Injection site pain was the most common local SAR, and fatigue, headache, and myalgia were the most common systemic SARs reported.
There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest.
Moderna plans to present these data at an upcoming medical conference and submit them for peer-reviewed publication. The company will engage with regulators on filing submissions for mRNA-1010.
Earlier this month, the U.S. Food and Drug Administration (FDA) expanded approval of Moderna&#8217;s respiratory syncytial virus vaccine to adults aged 18-59 at <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45921359/fda-expands-modernas-rsv-vaccine-use-to-at-risk-adults-aged-18-59-amid-cdc-panel-shake-up" rel="noreferrer noopener">increased risk for disease</a>.
The mRNA-based shot showed significant immune responses in adults with underlying health conditions and maintained a favorable safety profile. The vaccine was previously limited to adults 60 and older, where it demonstrated 79% efficacy against RSV symptoms.
Price Action: MRNA stock is up 3.31% at $28.06 during the premarket session at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" target="_blank" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a></li>
</ul>
Image via Shutterstock

Movers

Moderna's mRNA Flu Vaccine Outperforms Standard Shots

Moderna shares are trading higher after the company reported results from its Phase 3 efficacy study evaluating its mRNA-1010 seasonal influenza vaccine in adults.

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older
CAMBRIDGE, MA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 30, 2025 / Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. Additionally, strong rVE was observed for each influenza strain contained in the vaccine, including A/H1N1 (rVE=29.6%), A/H3N2 (rVE=22.2%), and the B/Victoria lineages (rVE=29.1%). Subgroup analyses confirmed a consistently strong rVE point estimate across age groups, risk factors and previous influenza vaccination status. In participants aged 65 years and older, mRNA-1010 demonstrated an rVE of 27.4%.
In a previous Phase 3 study, mRNA-1010 had already demonstrated superior seroconversion rates and geometric mean titer ratios (GMR) against all strains included in the vaccine compared to both high-dose and standard-dose licensed seasonal influenza vaccine. [1]
According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work. [3]
P304 (<a href="https://pr.report/bx98"> NCT06602024</a> ) is a Phase 3, randomized, observer-blind, active-controlled, case-driven, pivotal efficacy, immunogenicity and safety study. The trial enrolled 40,805 adults aged 50 years and older across 11 countries. Participants were randomly assigned to receive either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months.
Safety and tolerability of mRNA-1010 were consistent with reported results from a previous Phase 3 study. [4] The majority of solicited adverse reactions (SARs) were mild. Injection site pain was the most common local SAR, and fatigue, headache and myalgia were the most common systemic SARs reported. There were no significant differences between the groups in the rates of unsolicited adverse events, serious adverse events, or adverse events of special interest.
Moderna plans to present these data at an upcoming medical conference and submit for peer-reviewed publication. The Company will engage with regulators on filing submissions for mRNA-1010.

Moderna Reports Results From Phase 3 Efficacy Study Evaluating rVE Against Influenza Illness Of mRNA-1010 Versus Licensed Standard-Dose Seasonal Influenza Vaccine In Adults

<a href="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>
&nbsp;

U.S. CDC Advisory Panel Votes 5-1 In Favor Of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of Pregnant Women Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of All Adults Receiving Seasonal Flu Shot Only In Single Dose Forms That Are Free From Thimerosal

U.S. CDC Vaccine Advisory Panel Votes 7-0 In Favor Of Adding Preventive RSV Therapies To Vaccines For Children Resolution

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.
What Happened: On Wednesday, the Advisory Committee on Immunization Practices reconvened under controversy, just weeks after Kennedy dismissed all 17 previous members of the committee and replaced them with his appointees, according to Reuters.
Criticism has since intensified after the panel&#8217;s agenda was abruptly changed only one day before the meeting, while adding a presentation on thimerosal, a vaccine preservative whose alleged risks have been repeatedly debunked by mainstream science. 
The presentation was delivered by Lyn Redwood, former leader of Children&#8217;s Health Defense, an anti-vaccine organization originally founded by Kennedy himself.
The reconstituted panel is already seeing a fallout, with Dr. Michael Ross, one of the newly appointed members, resigning unexpectedly before the first meeting was held. Two other Centers for Disease Control and Prevention staff members also left amid the chaos.
At least half of Kennedy&#8217;s appointees have publicly questioned vaccine safety in the past, leading organizations such as the American Academy of Pediatrics, a non-voting participant of these meetings, to skip, citing a lack of scientific credibility and procedural transparency. The organization plans to publish its evidence-based childhood vaccine schedules instead.
The panel&#8217;s chair, Dr. Martin Kulldorff, stated that the committee would review individual vaccines, as well as the cumulative effects and scheduling of childhood immunizations.
The committee also postponed a key vote on an RSV vaccine intended for children, further heightening uncertainty around upcoming vaccine recommendations.
Why It Matters: The overhaul of the CDC's vaccine schedules stands to have a significant impact on pharma companies, especially those with exposure to childhood vaccines. 
For instance, Pfizer Inc. and Moderna Inc., with their Respiratory Syncytial Virus (RSV) vaccines, stand to see some headwinds due to the committee postponing its vote on the vaccine.
Similarly, Merck &amp; Co. Inc., having reported $540 million in revenue during its <a href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million">first quarter results</a> from its <a href="https://www.benzinga.com/trading-ideas/long-ideas/19/04/13514693/nyc-mandates-measles-vaccinations-merck-is-the-exclusive-manufacturer">measles-mumps-rubella (MMR) vaccine</a> series, could see a material impact as a result of the vaccine advisory committee&#8217;s stance.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Company</th>
<th>Potential Impact</th>
<th class="has-text-align-center" data-align="center">YTD Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Outsized exposure to childhood vaccination schedules, with its MMR series.</td>
<td class="has-text-align-center" data-align="center">-19.66%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>Delays in the approval of its RSV vaccines</td>
<td class="has-text-align-center" data-align="center">-8.83%</td>
</tr>
<tr>
<td>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)</td>
<td>RSV vaccine delays, along with the dropped COVID-19 vaccine mandate for pregnant women.</td>
<td class="has-text-align-center" data-align="center">-36.05%</td>
</tr>
</tbody>
</table>
</figure>
Price Action: Merck shares were down 0.81% on Wednesday, trading at $79.67, with the stock trading up 0.04% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="147" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-1024x147.png" alt="" class="wp-image-962643" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-1024x147.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM-768x110.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26030246/Screenshot-2025-06-26-at-12.32.31-PM.png 1536w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Merck scores well on Growth in Benzinga&#8217;s Edge Stock Rankings, with a favorable price trend in the short term. How does it compare with Pfizer and Moderna? Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> to find out.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46106134/bernie-sanders-shares-first-thing-he-would-do-as-president-and-it-could-be-a-jab-at-elon-musk" target="_blank" rel="noreferrer noopener">Bernie Sanders Shares First Thing He Would Do As President — And It Could Be A Jab At Elon Musk</a></li>
</ul>
Photo courtesy: lev radin / Shutterstock.com

Politics

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

<a href="https://www.youtube.com/watch?v=2PnYYb_xj3U">https://www.youtube.com/watch?v=2PnYYb_xj3U</a>
&nbsp;

Trump Nominee For U.S. CDC Director Monarez Tells Senate Panel She Has Not Seen A Causal Link Between Vaccines And Autism

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Moderna. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 13% leaning bullish and 80% bearish. Among these notable options, 5 are puts, totaling $278,750, and 10 are calls, amounting to $660,422.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $35.0 for Moderna, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Moderna stands at 4256.3, with a total volume reaching 4,555.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $22.5 to $35.0, throughout the last 30 days.
<h3>Moderna 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750269641_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.6</td>
<td>$22.50</td>
<td>$161.3K</td>
<td>1.0K</td>
<td align="right">889</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$22.50</td>
<td>$106.0K</td>
<td>1.0K</td>
<td align="right">200</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/18/26</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$25.00</td>
<td>$81.2K</td>
<td>155</td>
<td align="right">218</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$5.85</td>
<td>$5.8</td>
<td>$5.85</td>
<td>$25.00</td>
<td>$73.1K</td>
<td>5.6K</td>
<td align="right">126</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$35.00</td>
<td>$73.0K</td>
<td>544</td>
<td align="right">170</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Moderna</h3>
<ul>
<li>Currently trading with a volume of 4,186,511, the MRNA's price is down by -0.2%, now at $25.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About Moderna</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $26.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Underweight rating on Moderna, which currently sits at a price target of $26. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Moderna's Options: A Look at What the Big Money is Thinking

<a href="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use" title="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use">https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use</a>

'RFK Jr. Weighs Review of Dozens of Shots, Citing Aluminum Use' - Bloomberg News

<a href="https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles" title="https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles">https://www.statnews.com/2025/06/18/vinay-prasad-fda-cber-chief-medical-science-officer-advise-makary/#:~:text=Prasad%20will%20serve%20as%20the,have%20been%20two%20distinct%20roles</a>.

'Vinay Prasad Named Chief Medical And Science Officer At FDA' - STAT News

Caris Life Sciences, an AI-driven precision oncology company, is targeting a $5.35 billion valuation in its U.S. initial public offering, aiming to raise up to $423.5 million.&nbsp;
The Irving, Texas-based firm, backed by investment giants Sixth Street and Neuberger Berman, has already conducted 6.5 million molecular tests across 849,000 patient cases, establishing partnerships with over 100 biopharmaceutical firms, including Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), according to its <a href="https://www.sec.gov/Archives/edgar/data/2019410/000110465925057593/tm2415719-16_s1a.htm">prospectus</a> filed with the U.S. Securities and Exchange Commission.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">Valuation Context and Financial Performance</h2>
The $5.35 billion target—based on 23.5 million shares priced between $16 and $18 each—marks a notable shift from Caris' 2021 private valuation of $7.83 billion, Reuters reported, reflecting both market recalibration and the challenges of commercializing precision medicine.&nbsp;
According to its filing, Caris generated $412.3 million in revenue in 2024—a 35% year-over-year increase—while posting a net loss of $257.1 million. In Q1 2025, the company reported $120.9 million in revenue and a narrowed net loss of $127 million, compared to $80.7 million in revenue and a $134.1 million loss during the same period in 2024, according to its filing—signaling improving margins and sustained top-line growth.
At its proposed valuation, Caris would trade at approximately 13 times sales, a premium to peers like Guardant Health (NASDAQ: GH) and Tempus AI (NASDAQ: TEM), Reuters reported.&nbsp;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Technology and Competitive Edge</h2>
According to the company's website, Caris was founded in 2008 by entrepreneur David D. Halbert, who was inspired by his father's cancer battle to develop more effective, data-driven diagnostics. Today, the company operates from its North Texas headquarters and has offices in Phoenix, New York, Cambridge, Massachusetts, Tokyo, Japan, and Basel, Switzerland, serving both U.S. and international markets.
Caris' proprietary AI platform, which integrates molecular science with machine learning, analyzes comprehensive genomic, transcriptomic, and proteomic data to guide cancer treatment. The company holds 27 issued patents along with over 170 applications pending worldwide, according to its website. Its flagship MI Cancer Seek test, cleared by the U.S. Food and Drug Administration in 2023, detects early-stage malignancies with what the company claims is unmatched accuracy, the <a href="https://www.carislifesciences.com/about/news-and-media/caris-life-sciences-receives-fda-approval-for-mi-cancer-seek/#:~:text=MI%20Cancer%20Seek%20is%20available,Halbert%2C%20DSc%20(h.c.).">company</a> said at the time.&nbsp;
<h2 class="wp-block-heading">Investor Sentiment and Sector Implications</h2>
Caris will trade on the Nasdaq under the symbol CAI The offering is led by BofA Securities, J.P. Morgan Securities LLC, Goldman Sachs &amp; Co. LLC, and Citigroup Global Markets. <a href="https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-diagnostics-market">Grand View Research</a> projects a 22.5% CAGR in the AI cancer diagnostics market through 2030, highlighting strong growth potential in this sector.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>
Neuberger Berman has indicated it may purchase up to $75 million worth of shares in the IPO—signaling insider confidence in the company's long-term potential, according to Reuters.
<h2 class="wp-block-heading">Regulatory and Market Risks</h2>
Caris Life Sciences currently has one FDA-cleared diagnostic test, MI Cancer Seek, according to its filing.&nbsp;
Caris' pipeline includes investigational tools like FOLFIRSTai, an AI-based test for predicting chemotherapy response in metastatic colorectal cancer. While clinically validated, it remains unapproved by the FDA, according to the SEC filing, and stricter regulations could delay its commercialization.
<h2 class="wp-block-heading">Conclusion: A Litmus Test for AI Biotech</h2>
Caris's proposed IPO is drawing attention as a potential marker for the viability of AI-driven healthcare, with Reuters noting the offering comes amid renewed interest in precision diagnostics.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
Image: Shutterstock

ABBV

AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine

Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.&#8217;s overhaul of the Centers for Disease Control and Prevention&#8217;s key vaccine advisory panel threatens public health and <a href="https://www.benzinga.com/news/25/06/45937422/rfk-jr-appointee-to-cdc-advisory-committee-was-a-paid-expert-in-mercks-gardasil-lawsuit">undermines decades of immunization progress</a>.
What Happened: Seventeen ousted members of the CDC&#8217;s Advisory Committee on Immunization Practices published a warning in the JAMA medical journal on Monday, condemning Kennedy&#8217;s abrupt dismissal of the entire panel on June 9.
Kennedy replaced them with eight new members, including vaccine critics Robert Malone and Retsef Levi.
&#8220;The abrupt dismissal of the entire membership of the ACIP, along with its executive secretary, on June 9, the appointment of 8 new ACIP members just 2 days later, and the recent reduction of CDC staff dedicated to immunizations have left the U.S. vaccine program critically weakened,&#8221; the former members wrote.
See Also: <a href="https://www.benzinga.com/crypto/25/06/45967028/max-keiser-once-predicted-bitcoin-could-hit-a-300-trillion-market-cap-heres-how-much-1-btc-would-be-worth-if-that-happens">Max Keiser Once Predicted Bitcoin Could Hit A $300 Trillion Market Cap — Here&#8217;s How Much 1 BTC Would Be Worth If That Happens</a>
Why It Matters: Kennedy justified the overhaul to &#8220;re-establish public confidence in vaccine science,&#8221; claiming former President Joe Biden-appointed members had conflicts of interest without providing specific evidence. 
The committee advises the CDC on immunization schedules after U.S. Food and Drug Administration approval, directly influencing insurance coverage and vaccine policy, reported Reuters.
The panel shake-up compounds broader pharmaceutical industry disruption. The Trump administration <a href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report">terminated a $600 million</a> Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) contract for mRNA bird flu vaccine development and removed COVID-19 vaccines from recommended schedules for pregnant women and children.
Kennedy&#8217;s broader healthcare restructuring eliminated 10,000 U.S. Department of Health and Human Services positions to save $1.8 billion annually. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45967060/senate-republicans-unveil-trump-tax-and-health-plan-with-5-trillion-debt-ceiling-hike-tighter-medicaid-rules-in-the-big-beautiful-bill">Senate Republicans Unveil Trump Tax And Health Plan With $5 Trillion Debt Ceiling Hike, Tighter Medicaid Rules In The &#8216;Big, Beautiful Bill&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts

The U.S. Food and Drug Administration (FDA) expanded approval of Moderna Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) respiratory syncytial virus vaccine to adults aged 18-59 at increased risk for disease.
What Happened: The FDA on Thursday approved broader use of Moderna&#8217;s mRESVIA vaccine for younger at-risk adults based on late-stage trial results, reported Reuters.
The mRNA-based shot showed significant immune responses in adults with underlying health conditions and maintained a favorable safety profile. The vaccine was previously limited to adults 60 and older, where it demonstrated 79% efficacy against RSV symptoms.
Health Secretary Robert F. Kennedy Jr. simultaneously <a href="https://www.benzinga.com/news/health-care/25/06/45898417/rfk-jr-appoints-vaccine-critics-to-cdc-vaccine-panel-after-firing-entire-advisory-committee-report">appointed eight new members to the CDC&#8217;s Advisory Committee</a> on Immunization Practices, including prominent mRNA vaccine critics Robert Malone and Retsef Levi.
The health secretary fired all 17 existing panel members, claiming the need to <a href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading">&#8220;re-establish public confidence in vaccine science.&#8221;</a> The committee provides crucial guidance on vaccine recommendations that influence insurance coverage and policy.
The CDC currently recommends RSV vaccines for adults 75 and older, plus those 60-74 at increased risk. The final CDC recommendation remains pending for the expanded age group before availability.
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45919422/trumps-one-big-beautiful-bill-is-the-largest-redistribution-from-poor-to-rich-in-american-history-says-economist-justin-wolfers-amid-tax-cuts-spending-s">Trump&#8217;s &#8216;One Big, Beautiful Bill&#8217; Is &#8216;The Largest Redistribution From Poor To Rich In American History,&#8217; Says Economist Justin Wolfers Amid Tax Cuts, Spending Slashes And Tariffs</a>
Why It Matters: William Blair analysts noted the <a href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals">approval represents</a> &#8220;an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines.&#8221; However, they cautioned that approval alone won&#8217;t massively boost COVID vaccine sales, which depend primarily on overall vaccination market sentiment.
The advisory panel restructuring creates regulatory uncertainty for vaccine manufacturers. Kennedy&#8217;s broader policy changes include removing COVID vaccines from <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">recommended schedules for healthy children and pregnant women</a>, plus terminating Moderna&#8217;s $600 million bird flu vaccine contract.
RSV hospitalizes 15,000-20,000 U.S. adults aged 50-59 annually. Competing vaccines from Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and GSK plc (LSE: GSK) also target similar demographics, intensifying market competition amid shifting federal oversight. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45919626/coinbase-ceo-brian-armstrong-teases-crypto-credit-card-powered-by-american-express-bitcoin-cashbacks-offered-but-heres-the-catch">Coinbase CEO Brian Armstrong Teases Crypto Credit Card Powered By American Express—Bitcoin Cashbacks Offered, But Here&#8217;s The Catch</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Lutsenko_Oleksandr / Shutterstock.com

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older

Reported Earlier, Moderna's RSV Vaccine mRESVIA Approved By FDA For Adults Aged 18–59 With Underlying Health Conditions

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC&#8217;s Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after <a href="https://www.benzinga.com/news/health-care/25/06/45853393/robert-kennedy-jr-axes-entire-cdc-vaccine-panel-to-restore-public-trust-pfizer-moderna-other-biotech-stocks-drop-in-after-hours-trading">dismissing all 17 existing advisers</a>.
What Happened: The reconstituted panel includes Robert Malone, a prominent mRNA vaccine opponent aligned with Kennedy&#8217;s Make America Healthy Again movement, and Retsef Levi, who has called for the immediate withdrawal of mRNA vaccines, citing serious harm risks, according to a Reuters report.
The committee advises the CDC on immunization schedules after FDA approval, directly influencing insurance coverage and vaccine policy.
Kennedy justified the overhaul to &#8220;re-establish public confidence in vaccine science,&#8221; claiming prior Biden-appointed members had conflicts of interest without providing specific evidence. The new eight-member committee represents the minimum allowed under ACIP&#8217;s founding charter. See Also:<a href="https://www.benzinga.com/markets/equities/25/06/45897549/jim-cramer-says-america-wont-be-truly-liberated-until-it-strikes-rare-earth-deals-with-other-countries-us-doesnt-have-the-cards"> Jim Cramer Says America Won&#8217;t Be &#8216;Truly Liberated&#8217; Until It Strikes Rare-Earth Deals With Other Countries: US Doesn&#8217;t &#8216;Have The Cards&#8217;</a>
Why It Matters: Kennedy previously fired the entire 17-member panel Monday through a Wall Street Journal op-ed, arguing it had become a &#8220;rubber stamp for any vaccine.&#8221;
The Trump administration simultaneously terminated a $600 million Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) contract for mRNA bird flu vaccine development and removed COVID-19 vaccines from recommended schedules for <a href="https://www.benzinga.com/news/health-care/25/06/45810364/rfk-jr-champions-medical-freedom-while-curtailing-access-say-public-health-experts">healthy pregnant women and children</a>. Kennedy&#8217;s broader <a href="https://www.benzinga.com/government/regulations/25/03/44519638/us-department-of-health-and-human-services-aligns-with-trumps-executive-order-to-cut-10k-jobs-save-18-billion">healthcare restructuring eliminated</a> 10,000 HHS positions to save $1.8 billion annually.
Market reaction was mixed, with Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares declining marginally while Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose in after-hours trading. Earlier this year, <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">FDA&#8217;s top vaccine official</a>, Peter Marks, resigned after condemning Kennedy&#8217;s &#8220;misinformation and lies.&#8221;
The new panel will attend the June 25 ACIP meeting, originally scheduled to deliberate flu shots and 2025-26 COVID-19 booster recommendations. Critics argue Kennedy&#8217;s &#8220;medical freedom&#8221; messaging contradicts policies that restrict vaccine access. Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45897537/jamie-dimon-recalls-first-palantir-meeting-holy-christ-this-is-unbelievable-jpmorgan-now-has-600-ai-use-cases-2-billion-annual-investment-on-ai">Jamie Dimon Recalls First Palantir Meeting: &#8216;Holy Christ, This Is Unbelievable—&#8217; JPMorgan Now Has 600 AI Use Cases, $2 Billion Annual Investment On AI</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: lev radin / Shutterstock.com

RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report

Press Releases

Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

Events

Moderna to Present at Upcoming Conferences in June 2025

Moderna Announces Update on Investigational Pandemic Influenza Program

Legal

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

Commodities

Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

FHTX

NNVC

REGN

SANA

SMMT

VRTX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

JP Morgan

Barclays

RBC Capital

Evercore ISI Group

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Moderna

Interés en corto

Moderna (NASDAQ:MRNA) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL